drugset / Trial / NCT05811351

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT05811351

Phase 2 Completed 305 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Timeline

Start
2023-03-06
Primary completion
2026-02-23
Completion
2026-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject AAVCAGsCD59 Gene therapy (AAV / viral vector) Intravitreal
Background Prednisone Other / unclassified Oral
Background Triamcinolone Other / unclassified Other